Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Zhang S, Zhao J, Ling X, et al. (2026). "Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial.". Translational breast cancer research : a journal focusing on translational research in breast cancer. https://doi.org/10.21037/tbcr-2026-0056